Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

584 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M. Di Giacomo AM, et al. Among authors: giannarelli d. Lancet Oncol. 2012 Sep;13(9):879-86. doi: 10.1016/S1470-2045(12)70324-8. Epub 2012 Aug 13. Lancet Oncol. 2012. PMID: 22894884 Clinical Trial.
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, Biagioli M, Altomonte M, Maio M. Di Giacomo AM, et al. Among authors: giannarelli d. Cancer Immunol Immunother. 2011 Apr;60(4):467-77. doi: 10.1007/s00262-010-0958-2. Epub 2010 Dec 18. Cancer Immunol Immunother. 2011. PMID: 21170646 Free PMC article. Clinical Trial.
A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study.
Vici P, Giotta F, Di Lauro L, Sergi D, Vizza E, Mariani L, Latorre A, Pizzuti L, D'Amico C, Giannarelli D, Colucci G. Vici P, et al. Among authors: giannarelli d, d amico c. Oncology. 2011;81(3-4):230-6. doi: 10.1159/000334432. Epub 2011 Nov 17. Oncology. 2011. PMID: 22094540 Clinical Trial.
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, Biagioli M, Altomonte M, Maio M. Di Giacomo AM, et al. Among authors: giannarelli d. Cancer Immunol Immunother. 2013 Jun;62(6):1021-8. doi: 10.1007/s00262-013-1418-6. Epub 2013 Apr 17. Cancer Immunol Immunother. 2013. PMID: 23591982 Free PMC article.
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.
Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, Chiarion-Sileni V, Ferrucci P, Giannarelli D, Testori A, Ridolfi R, Maio M. Altomonte M, et al. Among authors: giannarelli d. J Exp Clin Cancer Res. 2013 Oct 25;32(1):82. doi: 10.1186/1756-9966-32-82. J Exp Clin Cancer Res. 2013. PMID: 24423086 Free PMC article.
584 results